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OBJECTIVE — TostudytheassociationoftheinﬂammatorymarkersserumamyloidA(SAA)
and C-reactive protein (CRP) with retinal microvascular parameters in hypertensive individuals
with and without type 2 diabetes.
RESEARCH DESIGN AND METHODS — This cross-sectional analysis was a substudy
in 711 patients (159 with and 552 without diabetes) of the Anglo-Scandinavian Cardiac Out-
comesTrial(ASCOT)basedondigital30-degreeimagesofsuperiorandinferiortemporalretinal
ﬁelds.
RESULTS — SAA was associated with arteriolar length-to-diameter ratio positively in nondi-
abetic patients (Ptrend  0.028) but negatively in diabetic patients (Ptrend  0.005). The differ-
ence was unlikely to be a chance ﬁnding (P  0.007 for interaction). Similar results were found
for the association of SAA with arteriolar tortuosity (P  0.05 for interaction). Associations were
less pronounced for CRP and retinal parameters.
CONCLUSIONS — Inﬂammatory processes are differentially involved in retinal microvas-
cular disease in diabetic compared with nondiabetic hypertensive individuals.
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R
etinal microvascular changes have
been associated with inﬂammatory
processes, which in turn have been
shown to be involved in the pathogenesis
of vascular disease (1–3). Serum amyloid
A (SAA) is a sensitive indicator of inﬂam-
mation with an expanded range and ki-
neticsdifferentfromthoseassociatedwith
C-reactive protein (CRP) (4). Although
levels of SAA and CRP have been shown
to be associated with retinal vessel di-
mensions (2), it is currently unknown
whether this association differs between
individuals with and without diabetes.
RESEARCH DESIGN AND
METHODS— This cross-sectional
analysis was a prespeciﬁed substudy at
two centers (London, U.K., and Dublin,
Ireland) of the Anglo-Scandinavian Car-
diacOutcomesTrial(ASCOT),arandom-
ized controlled multicenter trial assessing
the effect of two antihypertensive regi-
mens on coronary heart disease end
points (5–8). Ethics approval was ob-
tained at both study sites, and all partici-
pants gave written informed consent. In
addition to hypertension, individuals had
at least three of the following risk factors:
male sex, age 55 years, micro- or mac-
roproteinuria, smoking history, dyslipi-
demia, family history of premature CHD,
electrocardiogram abnormalities, left
ventricular hypertrophy, type 2 diabetes,
peripheral arterial disease, and previous
stroke or transient ischemic attack. Reti-
nal analyses were performed on digital
30-degree images of superior and inferior
temporal ﬁelds as previously described
(9). Arteriolar vessels were assessed up to
third-generation branches as prespeciﬁed
in the protocol. SAA and CRP concentra-
tions were measured on a Dade Behring
Nephelometer II (Dade Behring Diagnos-
tic, Marburg, Germany). Coefﬁcients of
variation for intra- and interassay preci-
sion were 5.2 and 8.5%, respectively
(10). Clinical and biochemical parame-
ters of diabetic and nondiabetic patients
were compared using Student’s t test; pa-
rameters were transformed if nonnor-
mally distributed. Values are given
as means  SD if normally distributed
and, otherwise, as median (interquartile
range).Multiplelinearregressionanalysis
was used to compare retinal parameters
between diabetic and nondiabetic indi-
viduals and to investigate the associations
between SAA or CRP and retinal parame-
ters. Prespeciﬁed explanatory variables
for all models were age, sex, BMI, smok-
ing status, and randomization to antihy-
pertensive and lipid-lowering treatment
in ASCOT. SAA and CRP were catego-
rized by tertiles and analyzed as categori-
cal and ordered factors (2). Statistical
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(Stata Corporation, College Station, TX).
RESULTS— This study included 711
individuals (159 with and 552 without
diabetes). Age was similar in diabetic and
nondiabetic patients (61.4  8.5 vs.
61.5  7.7 years, respectively; P  0.86),
and the proportion of female participants
was comparable (25.8 vs. 21.2%; P 
0.22). Diabetic patients had higher BMI
(30.6  5.4 vs. 28.8  4.3 kg/m
2; P 
0.001). Systolic blood pressure in dia-
betic and nondiabetic individuals was
159.1  19.1 vs. 159.5  16.9 mmHg,
respectively, (P  0.78); diastolic blood
pressure was 90.4  9.9 vs. 93.8  9.7
mmHg (P  0.001). Levels of CRP were
similar in diabetic and nondiabetic indi-
viduals (median 1.69 mg/l [interquartile
range 0.86–3.55] vs. 1.52 [0.77–3.39];
P  0.44), but SAA was signiﬁcantly
higher in diabetic than in nondiabetic in-
dividuals(3.15mg/l[2.05–4.90]vs.2.65
[1.60–4.60];P0.03).Diabeticindivid-
uals had shorter retinal arteriolar vessels
than nondiabetic individuals (446.9 
103.7vs.466.4126.8pixels;P0.03)
with larger diameters (29.3  3.1 vs.
28.3  3.2 pixels; P  0.001). This re-
sulted in a signiﬁcantly lower arteriolar
length-to-diameter (L:D) ratio in diabetic
individuals (12.8 [9.9–15.5] vs. 13.8
[11.2–17.0];P0.001).Arteriolartortu-
osity tended to be lower in diabetic than
in nondiabetic individuals, but differ-
ences were not statistically signiﬁcant
(1.25  10
2 [0.63–2.27] vs. 1.48 
10
2 [0.74–2.80]; P  0.31). Figure 1A
showstheassociationofSAAwitharterio-
lar L:D ratio in diabetic and nondiabetic
individuals. In diabetic patients, the asso-
ciation between SAA and arteriolar L:D
ratio was negative (Ptrend  0.005),
whereas in nondiabetic patients, levels of
SAA were positively associated with arte-
riolar L:D ratio (Ptrend  0.028). The
differences between diabetic and nondia-
betic patients were conﬁrmed in an inter-
actiontest(P0.007).Theassociationof
SAAandarteriolartortuosityshowedsim-
ilar ﬁndings (Fig. 1B; P  0.05 for inter-
action by diabetes status). No consistent
association was found for CRP and arte-
riolar L:D ratio (Fig. 1C), and there was a
positive association between CRP and ar-
teriolar tortuosity only for nondiabetic
patients (Ptrend  0.039). There were no
signiﬁcant associations between venular
parameters and either SAA or CRP.
CONCLUSIONS — Diabetes status
has a modifying effect on the association
ofSAAwithretinalarteriolararchitecture.
Whereas increased levels of SAA were as-
sociated with higher L:D ratio and tortu-
osity in nondiabetic patients, inverse
ﬁndings were observed in diabetic pa-
tients.Interactiontestsconﬁrmedthatthe
modifying effect of diabetes status was
unlikelytobeachanceﬁnding.CRPmea-
surements showed less consistent associ-
Figure1—AssociationofSAAandCRP(categorizedintertiles)witharteriolarL:Dratio(AandC)andwitharteriolartortuosity(BandD).Ranges
for tertiles 1, 2, and 3 (t1, t2, and t3, respectively) for SAA were 0.6–2.4, 2.5–3.9, and 4.0–92.6 mg/l, respectively, for diabetic individuals and
0.6–2.0, 2.1–3.6, and 3.7–162.0 mg/l for nondiabetic individuals. The corresponding values for CRP were 0.1–1.0, 1.0–2.7, and 2.8–49.8 mg/l for
diabetic individuals and 0.1–1.0, 1.0–2.4, and 2.4–65.2 mg/l for nondiabetic individuals. P values for trend are derived from multiple linear
regressionanalysismodelsadjustedforage,sex,BMI,smokingstatus,andantihypertensiveandlipid-loweringtreatmentintheASCOTandrepresent
the association between inﬂammatory markers and retinal parameters over the entire range of SAA or CRP. *P  0.05 for comparison with t1.
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to diabetes status.
Previous studies have consistently
shown an association of inﬂammatory
markers with retinal microvascular
changes but have not reported results ac-
cording to diabetes status (1–3). In the
BeaverDamEyeStudy,increasedlevelsof
SAA were associated with smaller arterio-
lar diameters (2). Because a smaller arte-
riolardiameterresultsinanincreasedL:D
ratio, these ﬁndings are compatible with
those for nondiabetic individuals in the
present analysis. It is noteworthy that
participants in the Beaver Dam Eye
Study mainly consisted of nondiabetic
individuals (7.1% with diabetes) and
exhibited a lower frequency of cardio-
vascularriskfactorsthanparticipantsin
the ASCOT (2).
CRP and SAA are classic acute-phase
proteins, and their levels are often corre-
lated (11). However, their concentration
maydifferduetodiverseregulationbythe
cytokine network and differences in
clearance rates (12). It is, therefore, not
surprising that these two markers may
differ in individuals with multiple and
different underlying pathologies, such as
hypertensive patients with and without
type2diabetes.Inparticular,recentstud-
ies have suggested that SAA may be a
more sensitive indicator of inﬂammation
in cardiovascular and noncardiovascular
diseasethanCRP(13–15),althoughother
studies have not conﬁrmed this (12).
The cross-sectional design of this
study limits conclusions regarding
cause and effect. Although analyses
were adjusted for relevant cardiovascu-
larriskfactors,thisdoesnotexcludethe
possibility that the analyses did not ac-
count for all potential confounders. In
conclusion,thepresentﬁndingssuggest
the involvement of diverse inﬂamma-
tory mechanisms for the development
of retinal microvascular disease in dia-
beticindividualscomparedwiththatfor
nondiabetic individuals—a concept
that may need further investigation.
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